# Oxford Immunotec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxford-immunotec

- Industry: Healthcare
- Headquarters: Abingdon, UK
- Website: www.oxfordimmunotec.com
- Total disclosed funding: $81M
- Latest round: Series D (Apr 30, 2010)
- Investors on record: 11

## About

Oxford Immunotec Ltd. is a company focused on advanced diagnostics, specializing in cell-mediated immune response testing, particularly for infectious diseases like tuberculosis, leveraging innovative technologies to enhance diagnostic accuracy.Founded in 2002, Oxford Immunotec Ltd. operates from Abingdon, UK, focusing on diagnostic testing solutions. In 2013, the company completed a TRADE SALE, raising USD 591.00 mn, primarily from PerkinElmer, Inc. The company has successfully executed 9 deals to date.Oxford Immunotec specializes in advanced diagnostic solutions driven by its T-SPOT Technology, an ELISPOT method that accurately measures immune responses. Its primary product, the T-SPOT.TB test, is essential for diagnosing tuberculosis and is utilized by clinical laboratories and healthcare professionals globally, ensuring effective monitoring of infections and immune responses.In the most recent financial year, 2023, Oxford Immunotec reported a revenue of USD 59.60 mn and an EBITDA of USD -3.24 mn, reflecting its operations and market presence in diagnostic testing services.The company is actively developing new diagnostic products aimed at expanding its market reach. Plans are underway to enter additional markets in Europe and Asia by 2025, utilizing the funds raised in the TRADE SALE to support these initiatives. The focus will be on enhancing its product offerings and increasing accessibility to its testing services.

## Funding rounds

- Series D, Apr 30, 2010, $26M — Molten Ventures, Wellington Partners, Clarus Ventures, New Leaf Venture Partners, National Technology Enterprises Company, SPARK Ventures, The Dow Chemical Company, Kaiser Permanente Ventures
- Series C, Oct 29, 2007, $40M — Quester Capital Management, Wellington Partners, Clarus Ventures, National Technology Enterprises Company, Prelude Ventures, The Dow Chemical Company
- Series B, Aug 3, 2005, $13M — Quester Capital Management, Longview Innovation, Prelude Ventures, The Dow Chemical Company
- Series A, Oct 1, 2003, $2.5M — Quester Capital Management

## Investors

- Quester Capital Management (https://capitalatlas.ai/funds/quester-capital-management) — Series A, Series B, Series C
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series B
- Prelude Ventures — Series B, Series C
- The Dow Chemical Company — Series B, Series C, Series D
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series C, Series D
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series C, Series D
- National Technology Enterprises Company — Series C, Series D
- Molten Ventures (https://capitalatlas.ai/funds/molten-ventures) — Series D
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series D
- SPARK Ventures — Series D
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series D